Therapeutic advances in rheumatology with the use of recombinant proteins.
Antibody engineering and protein design have led to the creation of a new era of targeted anti-inflammatory therapies in rheumatology. Recombinant DNA technologies have enabled the selection and humanization of specific antibody fragments in order to develop therapeutic reagents of any specificity that can be 'armed' to deliver effective anti-inflammatory 'payloads'. Antibodies and antibody-like proteins provide the opportunity to block key soluble mediators of inflammation in their milieu, or alternatively to block intracellular inflammation-triggering pathways by binding to an upstream cell-surface receptor. These designer proteins can be tuned for desired pharmacokinetic and pharmacodynamic effects, and represent tools for specific therapeutic intervention by delivering precisely the required immunosuppressive effect. The extent of desired and undesired effects of a particular biologic therapy, however, can be broader than initially predicted and require careful evaluation during clinical trials. This Review highlights advances in recombinant technologies for the development of novel biologic therapies in rheumatology.
Rothe
Achim
A
Department of Internal Medicine at the University Hospital of Cologne, Cologne, Germany. achim.rothe@uk-koeln.de
Power
Barbara E
BE
Hudson
Peter J
PJ
D000818:Animals; D000906:Antibodies / Q000737:chemistry / Q000627:therapeutic use*; D015195:Drug Design; D006801:Humans; D015394:Molecular Structure; D015202:Protein Engineering; D011994:Recombinant Proteins / Q000737:chemistry / Q000627:therapeutic use*; D012216:Rheumatic Diseases / Q000188:drug therapy*; D012219:Rheumatology / Q000639:trends*
D000906:Antibodies; D011994:Recombinant Proteins